Archon Partners’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q1 | – | Sell |
-260,000
| Closed | -$9.57M | – | 58 |
|
|
2020
Q4 | $9.57M | Sell |
260,000
-14,040
| -5% | -$515K | 1.29% | 36 |
|
|
2020
Q3 | $9.54M | Hold |
274,040
| – | – | 1.5% | 31 |
|
|
2020
Q2 | $8.5M | Sell |
274,040
-58,550
| -18% | -$1.99M | 1.55% | 28 |
|
|
2020
Q1 | $10.3M | Sell |
332,590
-105
| -0% | -$3.58K | 2.23% | 20 |
|
|
2019
Q4 | $12.4M | Hold |
332,695
| – | – | 2.11% | 23 |
|
|
2019
Q3 | $11.3M | Hold |
332,695
| – | – | 2.2% | 22 |
|
|
2019
Q2 | $13.7M | Hold |
332,695
| – | – | 2.71% | 14 |
|
|
2019
Q1 | $13.4M | Hold |
332,695
| – | – | 2.82% | 13 |
|
|
2018
Q4 | $13.8M | Hold |
332,695
| – | – | 3.44% | 6 |
|
|
2018
Q3 | $13.9M | Hold |
332,695
| – | – | 2.84% | 11 |
|
|
2018
Q2 | $11.5M | Hold |
332,695
| – | – | 2.48% | 16 |
|
|
2018
Q1 | $11.2M | Sell |
332,695
-1,423
| -0.4% | -$48.9K | 2.44% | 14 |
|
|
2017
Q4 | $11.5M | Hold |
334,118
| – | – | 2.5% | 17 |
|
|
2017
Q3 | $11.3M | Hold |
334,118
| – | – | 2.64% | 14 |
|
|
2017
Q2 | $10.6M | Hold |
334,118
| – | – | 2.47% | 17 |
|
|
2017
Q1 | $10.8M | Buy |
334,118
+4,216
| +1% | +$133K | 2.54% | 18 |
|
|
2016
Q4 | $10.2M | Sell |
329,902
-14,756
| -4% | -$450K | 2.66% | 16 |
|
|
2016
Q3 | $11.1M | Hold |
344,658
| – | – | 2.94% | 10 |
|
|
2016
Q2 | $11.5M | Hold |
344,658
| – | – | 3.14% | 7 |
|
|
2016
Q1 | $9.69M | Buy |
344,658
+14,229
| +4% | +$406K | 2.67% | 16 |
|
|
2015
Q4 | $10.1M | Buy |
330,429
+7,905
| +2% | +$249K | 2.74% | 13 |
|
|
2015
Q3 | $9.61M | Buy |
322,524
+15,810
| +5% | +$507K | 2.84% | 13 |
|
|
2015
Q2 | $9.76M | Buy |
306,714
+3,162
| +1% | +$103K | 2.52% | 12 |
|
|
2015
Q1 | $10M | Buy |
303,552
+1,581
| +0.5% | +$50.3K | 2.53% | 13 |
|
|
2014
Q4 | $8.92M | Buy |
301,971
+13,702
| +5% | +$393K | 2.32% | 18 |
|
|
2014
Q3 | $8.09M | Buy |
288,269
+11,067
| +4% | +$311K | 2.22% | 18 |
|
|
2014
Q2 | $7.81M | Buy |
277,202
+12,648
| +5% | +$361K | 2.08% | 25 |
|
|
2014
Q1 | $8.06M | Buy |
264,554
+31,620
| +14% | +$943K | 2.27% | 23 |
|
|
2013
Q4 | $6.77M | Sell |
232,934
-20,026
| -8% | -$583K | 1.87% | 34 |
|
|
2013
Q3 | $6.89M | Sell |
252,960
-21,080
| -8% | -$574K | 2.09% | 24 |
|
|
2013
Q2 | $7.28M | Buy |
+274,040
| New | +$7.57M | 2.48% | 16 |
|
Other funds holding PFE
Archon Partners's PFE Position: Q1 2021 in Review
Archon Partners sold out of Pfizer (PFE) in Q1 2021, closing a stake of 260,000 shares — an estimated $9.57M sold.
Archon Partners first reported a position in PFE in Q2 2013 and held it in 31 quarters. The position peaked at $13.9M in Q3 2018. 2,676 funds tracked by Wall St. Rank hold PFE as of Q1 2021.
- Archon Partners reported no remaining Pfizer position as of Q1 2021 after selling out during the quarter.
- Archon Partners sold 260,000 Pfizer shares in Q1 2021, an estimated $9.57M.
- Archon Partners first reported a position in Pfizer in Q2 2013 and held it in 31 quarters.
- Archon Partners's Pfizer position peaked at $13.9M in Q3 2018.
- 2,676 funds tracked by Wall St. Rank held Pfizer as of Q1 2021.
Based on Archon Partners's 13F filing for Q1 2021, filed 17 May 2021.